The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is soliciting applications from U.S. and overseas research institutions seeking to become Clinical Trials Units (CTUs) in the Institute's revamped HIV/AIDS Clinical Trials Networks. NIAID, part of the U.S. National Institutes of Health (NIH), supports the world's largest portfolio of clinical research in HIV/AIDS prevention, vaccine and treatment research and development.

This solicitation, the second of two Requests for Applications (RFAs), is designed to increase the efficiency, accountability and integration of NIAID's HIV/AIDS clinical research networks and enhance their capacity to effectively conduct vital clinical research, especially in resource-limited settings.

The first solicitation, "Leadership for HIV/AIDS Clinical Trials Networks," was released in November 2004. The networks emerging from that RFA will focus on developing and evaluating treatments, prevention strategies and vaccines, with an emphasis on interventions that can be employed in resource-limited settings. The Clinical Trials Units funded in response to this RFA will carry out the research agendas of those networks in one or more of the following six priority areas of investigation:

Developing HIV vaccines

Translating research insights into therapies to treat HIV disease

Optimizing clinical management of HIV/AIDS, including co-infections and other HIV-related conditions

Developing microbicides to prevent HIV acquisition and/or transmission

Preventing mother-to-child transmission of HIV

Developing other methods of HIV prevention

"These Clinical Trials Units will help coordinate and carry out the next generation of AIDS research in the United States and globally," says NIAID Director Anthony S. Fauci, M.D. "Our goal is to develop the best possible leadership and research infrastructure to carry out a flexible, collaborative and c
'"/>

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
15-Feb-2005


Page: 1 2 3
Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID begins enrolling volunteers for novel HIV vaccine study
3. NIAID-sponsored clinical trial aims to boost flu vaccine supply
4. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
5. NIAID launches influenza genome sequencing project
6. NIAID launches program to improve medical tools against emerging infectious diseases
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial